Shortages of long-acting methylphenidate medications are expected to continue until the end of December, including Concerta and Teva-XR modified-release tablets and Ritalin LA and Rubifen LA capsules.
Ritalin 10mg immediate-release tablet shortages are expected to begin in July but Artige 10mg immediate-release tablets are still available, according to an alert from the TGA.
The regulator has approved overseas-registered substitute capsules in multiple strengths until the end of January 2026. However, these are not PBS-subsidised and TGA advice does not indicate price or availability.
To address the issue, the regulator convened a Medicine Shortage Action Group (MSAG), with input from nearly a dozen groups including the RACGP, AMA, ADHD Foundation and the Pharmaceutical Society of Australia.
The methylphenidate MSAG is advising prescribers to consider ongoing shortages of these products and be aware of the availability of other ADHD medicines. These can be found on the section 19A approvals database and currently include alternatives from Switzerland, Sweden, Denmark and the US.

